Chinese hamster ovary (CHO) cells, the powerhouse of the biopharmaceutical industry, are inherently variable. This functional heterogeneity is what makes them such a valuable tool for producing biotherapeutics, while also accounting for the considerable cost and time associated with cell line development (CLD). Karen Coss et al. at Valitacell explain why dealing with the consequences of clone-specific genetic and functional variation, and its acquisition during CLD, can be extremely time-consuming and labour-intensive.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/10/Chemstress_biomanufacturing-process-control.pdf” width=”100%” height=”900px” style=”border:0;”]